InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
April 28, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...
AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
March 22, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
January 21, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
November 30, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Patient screening and dosing ongoing in Turkey and HungaryTopline data expected in Q2 2021 for the Combination Trial DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production
November 10, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic,...
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
September 28, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
September 15, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Abstracts to Focus on: Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic...
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
July 07, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
May 28, 2020 03:00 ET
|
Atriva Therapeutics GmbH
ATR-002 mode of action inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in preclinical studiesAtriva’s lead product candidate is the only host-targeted antiviral...
PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
July 15, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...